Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Children’s Minnesota has backed the first close of 4Bio Ventures II, a $150m venture fund that will focus on areas such as cell and gene therapy.

The gene editing startup, a spinout from Yale University, has launched with funding from investors including GV and Kleiner Perkins.

TIAP, previously Mars Innovation, has lured drug firm Amgen to co-invest in portfolio businesses based on its members' health sciences research.

Trucode is advancing in vivo gene editing applications for disorders including sickle cell disease that grew from Yale research and has been backed by GV and Kleiner Perkins.

GCV Rising Star Paulo Braga, who leads Eurofarma’s corporate venturing fund, has spoken to Global Corporate Venturing about the unit's focus.

Healthcare management platform developer Vim has now received $37m since it was founded, with Premera Blue Cross and Optum Ventures among its newest investors.

Cash Capital has contributed to a a series C round for medical supplies provider GKHT, established as an affiliate of the Chinese Academy of Sciences-owned Osic Holding Group.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Harvard spinout Platelet BioGenesis has added $26m in series A1 financing to its coffers thanks to a consortium co-led by Ziff Capital Partners and Qiming Venture Partners USA.